Onkologie最新文献_第8页

Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab. 辅助曲妥珠单抗治疗her2阳性早期乳腺癌患者无复发生存的预后因素

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-09-16 DOI: 10.1159/000355156

Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Arife Ulas, Dogan Yazilitas, Oznur Bal, Mehmet Kucukoner, Nuriye Yildirim Ozdemir, Umut Demirci, Yusuf Gunaydin, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, Mahmut Gumus, Mustafa Benekli, Suleyman Buyukberber

{"title":"Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.","authors":"Onder Tonyali, Ugur Coskun, Nur Sener, Mevlude Inanc, Tulay Akman, Arife Ulas, Dogan Yazilitas, Oznur Bal, Mehmet Kucukoner, Nuriye Yildirim Ozdemir, Umut Demirci, Yusuf Gunaydin, Ramazan Yildiz, Halit Karaca, Olcun Umit Unal, Mahmut Gumus, Mustafa Benekli, Suleyman Buyukberber","doi":"10.1159/000355156","DOIUrl":"https://doi.org/10.1159/000355156","url":null,"abstract":"Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC).Patients and methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis.Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS.Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 10","pages":"554-8"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31793717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence. CD40在骶脊索瘤中的过表达及其与低复发率的关系。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-09-17 DOI: 10.1159/000355334

Xuefeng Li, Sijia Wang, Yan Chen, Guifeng Liu, Xiaoyu Yang

{"title":"Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence.","authors":"Xuefeng Li, Sijia Wang, Yan Chen, Guifeng Liu, Xiaoyu Yang","doi":"10.1159/000355334","DOIUrl":"https://doi.org/10.1159/000355334","url":null,"abstract":"Aim: To determine the degree of CD40 overexpression in sacral chordomas and its correlation with tumor recurrence.Methods: CD40 or CD31 overexpression was determined by immunohistochemical staining; the microvessel density (MVD) was calculated according to the CD31 expression. The correlation of CD40 over-expression with tumor recurrence was analyzed.Results: 56% of the specimens from 36 cases of sacral chordomas overexpressed CD40, which is a significantly higher percentage than for the 2 specimens in 10 in normal notochordal tissue (p < 0.05). 36.84% of the specimens of the 19 recurrent cases were CD40 overexpressing, in contrast to less than 76.47% in the no-recurrence group (p < 0.05). Multivariate analysis demonstrated that CD40 overexpression and the resection margins were independent factors contributing to tumor recurrence. The MVD value was 25.71 ± 8.86 mm(-2) in the sacral chordomas and more than 6.63 ± 2.45 mm(-2) in the normal embryonic notochord tissue (p < 0.01). The MVD value in the recurrence group (30.08 ± 7.11 mm(-2)) was significantly higher than that of the no-recurrence group (20.82 ± 8.18 mm(-2); p < 0.05). But the MVD value was significantly lower in the CD40-overexpressing group than in the CD40-less expressing group (p < 0.05).Conclusions: CD40 was overexpressed in sacral chordomas, and the overexpression was not dependent on the intratumoral MVD. CD40 overexpression was correlated with low recurrence of the tumor, implying that CD40 plays an important role in the antitumor response against sacral chordomas and in the inhibition of tumor recurrence.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 10","pages":"567-71"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31793719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status. trabectedin在2例具有野生型Asp1104 ERCC5肿瘤状态的转移性骨肉瘤患者中的主要疗效

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-10-14 DOI: 10.1159/000355664

Lauris Gastaud, Esma Saâda-Bouzid, Valérie Le Morvan, Philippe Pourquier, Antoine Ianessi, Juliette Thariat, Antoine Italiano, Antoine Thyss

{"title":"Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.","authors":"Lauris Gastaud, Esma Saâda-Bouzid, Valérie Le Morvan, Philippe Pourquier, Antoine Ianessi, Juliette Thariat, Antoine Italiano, Antoine Thyss","doi":"10.1159/000355664","DOIUrl":"https://doi.org/10.1159/000355664","url":null,"abstract":"Background: Treatment of osteosarcoma of the extremities consists of surgical resection preceded and followed by chemotherapy, including high-dose methotrexate or adriamycin-based protocols. When distant relapse occurs, therapeutic options are scarce. Trabectedin, a DNA-binding agent, is indicated for the treatment of patients with advanced soft tissue sarcomas after failure of anthracyclines and ifosfamide. In this indication, the 6-month progression-free survival is about 35-40%. Recent reports showed that some specific single nucleotide polymorphisms (SNPs) from DNA repair genes could be associated with sensitivity to trabectedin in soft tissue sarcomas.Case reports: We report our experience of 2 metastatic, heavily pre-treated osteosarcoma patients who were treated with trabectedin. Pyrosequencing analyses of tumors from both patients for several SNPs of the ERCC1, ERCC5 and BRAC1 genes were performed. Both patients showed major response to trabectedin, which was interestingly related with homozygoty of the common guanine allele of ERCC5 (G/G genotype; Asp/Asp) after pyrosenquencing analysis of tumors from both patients. This polymorphism was previously shown to be associated with better outcome in soft tissue sarcoma patients treated with trabectedin.Conclusion: Homozygoty for the wild-type Asp1104 SNP of the ERCC5 gene was found in 2 cases of relapsed osteosarcoma, who responded to trabectedin.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 11","pages":"670-3"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355664","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31834781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Quality of life and symptom evaluation in daily oncology practice: a survey of 150 patients with advanced gastrointestinal tumours receiving palliative chemotherapy. 日常肿瘤学实践中的生活质量和症状评价:150例接受姑息性化疗的晚期胃肠道肿瘤患者的调查。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-01-28 DOI: 10.1159/000346670

Katharina Schultheis, Ralf-Dieter Hofheinz, Deniz Gencer, James A Blunk, Justus Benrath

{"title":"Quality of life and symptom evaluation in daily oncology practice: a survey of 150 patients with advanced gastrointestinal tumours receiving palliative chemotherapy.","authors":"Katharina Schultheis, Ralf-Dieter Hofheinz, Deniz Gencer, James A Blunk, Justus Benrath","doi":"10.1159/000346670","DOIUrl":"https://doi.org/10.1159/000346670","url":null,"abstract":"Background: Quality of life (QoL) is frequently investigated as a secondary endpoint in clinical trials but is rarely evaluated in clinical practice. The present survey sought to assess the QoL of patients with advanced gastrointestinal tumours receiving palliative chemotherapy. Furthermore, we wanted to compare the results of subscales of the generic EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire, version 3.0) using assessment tools with an emphasis on pain and depression.Patients and methods: 150 patients with gastrointestinal tumours undergoing palliative chemotherapy completed 3 questionnaires. QoL was assessed using the EORTC QLQ-C30, Beck depression inventory (BDI) was utilised to measure the severity of patients' depression and a visual analogue scale (VAS) was applied to measure patient's pain intensity. Correlations between these assessments were calculated.Results: The survey revealed that treatment of pain and depression appeared to be inadequate in the present cohort of patients with metastatic gastrointestinal cancer. Good correlations between EORTC QLQ-C30 subscales and the VAS (r = 0.86), as well as the BDI (r = 0.63) were found.Conclusion: The present analysis indicates the need for better symptom control regarding the examples 'pain' and 'depression'. In view of the good correlation between the EORTC QLQ-C30 and the BDI and VAS, further studies on the implementation of the EORTC QLQ-C30 as a screening tool, or for follow-up measurements in daily practice are warranted.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 1-2","pages":"33-7"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000346670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31255952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Effect of belly board with bladder compression device on small bowel displacement from the radiotherapy field for rectal cancer. 腹板加膀胱压迫装置对直肠癌放疗场小肠移位的影响。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-04-02 DOI: 10.1159/000350299

Yoonsun Chung, Hong I Yoon, Ki C Keum, Joo H Kim, Won H Choi, Ki C Nam, Woong S Koom

{"title":"Effect of belly board with bladder compression device on small bowel displacement from the radiotherapy field for rectal cancer.","authors":"Yoonsun Chung, Hong I Yoon, Ki C Keum, Joo H Kim, Won H Choi, Ki C Nam, Woong S Koom","doi":"10.1159/000350299","DOIUrl":"https://doi.org/10.1159/000350299","url":null,"abstract":"Background: The aim of this study was to investigate the effect of a belly board (BB) with the addition of a bladder compression device (BCD) for small bowel (SB) displacement from the radiotherapy field for rectal cancer.Patients and methods: Computed tomography (CT) scans of 38 rectal cancer patients positioned on a BB were analyzed and compared with CT scans from the same patients after the addition of a BCD. The BCD moves the inferior border of the BB from the pubic symphysis to the lumbosacral junction. The treated and irradiated volumes of the SB and bladder were compared. The irradiated volume ratio of SB to abdominopelvic cavity (APC) and that of bladder to APC were analyzed.Results: With the BCD, the treated and irradiated volumes of SB decreased significantly (49.1 ± 48.0 vs. 60.9 ± 50.9 cc, p = 0.006 and 207.5 ± 140.8 vs. 482.8 ± 214.2 cc, p < 0.001, respectively). The irradiated volume ratio of bladder to APC with the BCD increased considerably compared to that without the BCD (25.2 ± 11.5 vs. 18.7 ± 10.5%, p < 0.001), and the ratio of irradiated volume of SB to APC decreased significantly with the BCD (18.8 ± 12.4 vs. 31.8 ± 12.1%, p < 0.001).Conclusion: This study showed that the addition of a BCD to the BB could effectively provide further displacement of SB from the rectal cancer radiotherapy field.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 5","pages":"241-6"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000350299","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31443359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

microRNA-21 and its emerging role in tumor progression in systemic malignancies. microRNA-21及其在系统性恶性肿瘤进展中的新作用。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-06-28 DOI: 10.1159/000353693

Shailendra Kapoor

引用次数: 1

Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma. 以t细胞淋巴母细胞淋巴瘤为表现的慢性髓性白血病的髓外细胞危象。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-02-25 DOI: 10.1159/000348681

Jia Wei, Mei Huang, Ying Wang, Jianfeng Zhou

{"title":"Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma.","authors":"Jia Wei, Mei Huang, Ying Wang, Jianfeng Zhou","doi":"10.1159/000348681","DOIUrl":"https://doi.org/10.1159/000348681","url":null,"abstract":"Background: Chronic myeloid leukemia (CML) is usually diagnosed in the chronic phase. An extramedullary blast crisis mimicking a T-cell lymphoma is a rare finding.Case report: A 35-year-old man presented with multiple lymphadenopathy 2 months after diagnosis of Philadelphia chromosome (Ph)-positive CML in the chronic phase. Cervical lymph node biopsy later indicated an extramedullary blast crisis resembling T-cell lymphoblastic lymphoma (TLBL). The tumor mass was composed of primitive lymphoid cells expressing terminal deoxynucleotidyl transferase (TdT), CD3, CD43, CD5, CD99, and Bcl-2. Although the pathological diagnosis, confirmed by 2 independent pathological centers, was more typical of TLBL, fluorescence in situ hybridization (FISH) analysis showed the bcr-abl fusion gene within the blastic tumor cells. The FISH finding confirmed that the mass represented an extramedullary, immature blastic transformation of CML rather than a de novo T-cell lymphoma.Conclusion: The diagnosis of de novo TLBL should be suspected before excluding the extramedullary blast phase of CML.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 3","pages":"119-22"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000348681","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31394910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report. 在硼替佐米治疗转移性滤泡性甲状腺癌失败后成功使用索拉非尼1例报告。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-05-13 DOI: 10.1159/000351252

Florian Eisner, Renate Schaberl-Moser, Armin Gerger, Hellmut Samonigg, Martin Pichler

{"title":"Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.","authors":"Florian Eisner, Renate Schaberl-Moser, Armin Gerger, Hellmut Samonigg, Martin Pichler","doi":"10.1159/000351252","DOIUrl":"https://doi.org/10.1159/000351252","url":null,"abstract":"Background: Thyroid cancer (TC) is the most commonly diagnosed endocrine malignancy in developed countries. Differentiated thyroid carcinoma (DTC), which includes papillary thyroid carcinoma and follicular thyroid carcinoma (FTC), composes more than 90% of all TC cases. When DTC recurs or metastasizes to distant sites despite the use of local and radiotherapeutic treatment modalities, the currently effective treatment options are limited.Case report: A then 40-year-old female Caucasian patient was diagnosed with FTC and underwent surgery and postoperative radioactive iodine therapy. The patient developed metastatic disease, and palliative first-line treatment with the proteasome inhibitor bortezomib was initiated. After 3 months, the patient suffered progressive pulmonary metastatic disease. Treatment with the multikinase inhibitor sorafenib was started, and after 3 months of therapy, tumor restaging demonstrated partial remission. The treatment is ongoing, and the current progression-free survival is 16 months. With the exception of mild diarrhea and hand-foot syndrome, the therapy was well tolerated, and no grade 3/4 adverse toxicities occurred.Conclusion: In our single case of metastatic FTC, sorafenib showed clinically meaningful antitumor activity accompanied by good tolerability. This case report supports the use of this drug as a potential treatment option for advanced/metastatic FTC.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 6","pages":"368-70"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000351252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31512884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Supply legal and regulatory structure for restructuring the drug market]. [为重组药品市场提供法律和监管结构]。

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-05-07 DOI: 10.1159/000350947

Christian Dierks

{"title":"[Supply legal and regulatory structure for restructuring the drug market].","authors":"Christian Dierks","doi":"10.1159/000350947","DOIUrl":"https://doi.org/10.1159/000350947","url":null,"abstract":"Krankenversicherung noch den Preis entrichten muss, den der Hersteller selbst festgesetzt hat. Es liegt im Wesen dieses Systems, dass die Zeit bis zur Vereinbarung des Erstattungspreises als legitime Einfuhrungsphase keiner besonderen Wirtschaftlichkeitsprufung ausgesetzt ist. Regresse konnen also nicht deshalb verhangt werden, weil die Kosten des Arzneimittels in diesen ersten Monaten noch uber dem spater festgesetzten Erstattungspreis lagen. Fur Ipilimumab (Yervoy) wurde das Verfahren zur fruhen Nutzenbewertung inzwischen abgeschlossen. Das Arzneimittel ist zugelassen zur Behandlung von vorbehandelten erwachsenen Patienten mit fortgeschrittenen (nicht resezierbaren oder metastasierten) Melanomen. Fur Yervoy hat die Bewertung des G-BA einen Hinweis auf einen betrachtlichen Zusatznutzen ergeben. Auf dieser Basis haben sich der Spitzenverband Bund und der Hersteller des Arzneimittels ohne Schiedsstelle auf einen Erstattungsbetrag geeinigt. Die Vereinbarung gilt ruckwirkend ab dem 01.08.2012. Der neue Preis gilt nach § 130 b SGB V (Sozialgesetzbuch Funftes Buch) als wirtschaftlicher Erstattungsbetrag. Vereinbarungen dieser Art sollen vorsehen, dass Verordnungen des Arzneimittels von der Prufungsstelle als Praxisbesonderheiten anerkannt werden, wenn der Arzt bei der Verordnung im Einzelfall die dafur vereinbarten Anforderungen an die Verordnung ein gehalten hat. Diese Anforderungen sind in den Programmen zur Verordnung von Arzneimitteln, die von den kassenarztlichen Vereinigungen veroffentlicht werden, zu hinterlegen. Hierzu wird noch eine Veroffentlichung auf der Website des Spitzenverbandes Bund der Gesetzlichen Krankenversicherung erwartet. Diese wird ihre entsprechende Abbildung in den Prufvereinbarungen der einzelnen kassenarztlichen Vereinigungen finden. Entsprechend gelistete Arzneimittel gelten dann als Praxisbesonderheit. Ins gesamt wird das Gesetz dazu fuhren, dass durch die Bewertung des Zusatznutzens und die Vereinbarung eines Erstattungspreises die Verordnung von innovativen Arzneimitteln zukunftig regress sicher erfolgen kann.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 Suppl 4 ","pages":"12"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000350947","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31531275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer. 谷胱甘肽s -转移酶P1 (GSTP1)、x线修复交叉互补组1 (XRCC1)和5,10-亚甲基四氢叶酸还原酶(5,10- mthfr)基因多态性与晚期胃癌化疗反应的关系

IF 0.3 4区医学

Onkologie Pub Date : 2013-01-01 Epub Date: 2013-05-21 DOI: 10.1159/000351260

Mei Ji, Bin Xu, Jing-Ting Jiang, Jun Wu, Xiao-Dong Li, Wei-Qing Zhao, Hong-Yu Zhang, Wen-Jie Zhou, Chang-Ping Wu

{"title":"Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.","authors":"Mei Ji, Bin Xu, Jing-Ting Jiang, Jun Wu, Xiao-Dong Li, Wei-Qing Zhao, Hong-Yu Zhang, Wen-Jie Zhou, Chang-Ping Wu","doi":"10.1159/000351260","DOIUrl":"https://doi.org/10.1159/000351260","url":null,"abstract":"Background: Our study aimed to investigate the relationship between glutathione S-transferase P1 (GSTP1), 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) and X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms and the response to chemotherapy in advanced gastric cancer.Patients and methods: 59 cases of advanced gastric cancer were enrolled. All patients were treated with the DCF regimen comprising docetaxel, cisplatin, and 5-fluorouracil. All patients' genotypes regarding GSTP1, XRCC1, and 5,10-MTHFR were analyzed by polymerase chain reaction/ligase detection reaction (PCR-LDR).Results: There were 15 (25.42%) cases of G/G genotype, 21 (35.59%) of G/A genotype, and 23 (38.98%) of A/A genotype for GSTP1, 16 (27.12%) cases of A/A genotype, 18 (30.51%) of G/A genotype, and 25 (42.37%) of G/G genotype for XRCC1, and 21 (35.59%) cases of C/C genotype, 22 (37.29%) of C/T genotype, and 16 (27.12%) of T/T genotype for 5,10-MTHFR. After 2 cycles of chemotherapy, there were 4 cases of complete remission, 14 of partial remission, 19 of stable disease, and 22 of advanced disease, with a total effective rate of 30.51%. Better survival was shown for GSTP1 G/G genotype, XRCC1 A/A genotype, and 5,10-MTHFR T/T genotype (p < 0.05).Conclusion: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 6","pages":"335-40"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000351260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31606095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9